Abeona Therapeutics Inc.
ABEOHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframeAbeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. With a market capitalization of $329.4M, it sits in small-cap territory. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
Market Cap
$329.4M
Beta
1.34
P/E (TTM)
6.08
P/E (Fwd)
20.16
EPS (TTM)
$0.95
EPS (Fwd)
$0.29
ROE
71.0%
ROA
-38.9%
Cash
$168.3M
Total Debt
$23.2M
Free CF
-$56.6M
52W Change
-8.0%
Annual Financials
Cash vs Debt
Abeona Therapeutics Inc. holds $168.3M in cash against $23.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$56.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at 71.0%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $1.4M (2022) to $5.8M (2025), reflecting a 312% increase over the period.
With cash comfortably exceeding debt, ABEO has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Abeona Therapeutics Inc.'s trajectory.